South Korea's Ministry of Food and Drug Safety (MFDS) updates the stem cell therapy's approval in May 2026 — as the developer works to resume supply and build a U.S. research base SEOUL, South Korea, July 20, 2026 /PRNewswire/ --... The post Neuronata-R retains conditional approval in South Korea appeared first on Kosmo Digital .

The Ministry of Food and Drug Safety in South Korea has granted continued approval for Neuronata-R, a cell therapy for ALS, based on new clinical trial results, enhancing patient access.

South Korea's Ministry of Food and Drug Safety (MFDS) updates the stem cell therapy's approval in May 2026 — as the developer works to resume supply and build a U.S. research base SEOUL, South Korea, July 19, 2026 /PRNewswire/ -- Patients with amyotrophic lateral sclerosis (ALS) in South...

CorestemChemon is making significant strides in ALS stem cell therapy with Neuronata-R, focusing on regulatory processes in Korea and expanding into the U.S. market.

SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- CorestemChemon (KOSDAQ: 166480) is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an...

In a now-completed clinical trial, the stem cell therapy Neuronata-R was found to benefit ALS patients with slower disease progression.

Das südkoreanische Biotechnologieunternehmen CorestemChemon Inc. (KOSDAQ: 166480) hat auf dem PACTALS 2025-Kongress in Melbourne, Australien, Ergebnisse der Phase-3-Studie ALSUMMIT zu seiner Stammzelltherapie Neuronata-R® (Lenzumestrocel) für amyotrophe Lateralsklerose (ALS) präsentiert. Obwohl die Studie die primären und sekundären Endpunkte insgesamt nicht erreichte, zeigten Patienten mit langsameren Krankheitsverläufen signifikante Verbesserungen in der Funktionserhaltung und Atmungskapazität. In der Untergruppe der Slow-Progressor-Patienten führte Neuronata-R®, eine autologe Therapie mit mesenchymalen Stammzellen (MSC) aus dem Knochenmark, nach 12 Monaten zu einer ALSFRS-R-Skala von 31,2 Punkten gegenüber 26,4 im Placebo (p=0,001).

CorestemChemon's Neuronata-R® shows potential in ALS treatment, highlighting significant improvements in specific patient subgroups at PACTALS 2025.

Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precision-medicine approach and potential FDA accelerated pathway SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key...

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company officials confirmed to BioWorld during a June ...

Neuronata-R®, a stem cell therapy for ALS, shows significant efficacy in patients. The findings support a path toward FDA accelerated approval, promising new hope.

I play many roles, the least important of which is that of an ALS patient.

Corestem Chemon’s stock price hit its daily lower limit as soon as the market opened on Wednesday, following the company's announcement that its phase 3 clinical trial for Neuronata-R, a stem cell the...

Corestem Chemon’s stock price hit its daily lower limit as soon as the market opened on Wednesday, following the company's announcement that its phase 3 clinical trial for Neuronata-R, a stem cell the...